UPDATE 2-Ophthotech may get over $1 bln from eye drug deal with Novartis
Reuters Ophthotech is testing Fovista in late-stage studies to treat wet age-related macular degeneration (AMD), in combination with standard treatments including Regeneron Pharmaceuticals Inc’s Eylea and Roche Holding AG’s Avastin and Lucentis. Ophthotech … |
Source: Wet Macular Degeneration News From Google News